Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce
mortality and cardiovascular morbidity among patients with myocardial infarction …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …

Background—The elderly constitute an increasing proportion of acute myocardial infarction
patients and have disproportionately high mortality and morbidity. Those with heart failure or …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Abstract Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
compared outcomes with:(1) angiotensin‐converting enzyme inhibition (ACEI) with the …

Abstract The Survival and Ventricular Enlargement (SAVE) Study demonstrated that long-
term administration of the angiotensin-converting enzyme inhibitor captopril to recent …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Background ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve
survival and reduce morbidity in patients with acute myocardial infarction and evidence of …

Background: The role of angiotensin-receptor blockers (ARBs) in treating patients with
chronic heart failure and high-risk acute myocardial infarction (MI) has been controversial …